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SYNOPSIS 
Liver damage leads to an inflammatory response and to the activation and proliferation of 
mesenchymal cell populations within the liver which re-model the extracellular matrix as 
part of an orchestrated wound-healing response.  Chronic damage results in a progressive 
accumulation of scarring proteins (fibrosis) that with increasing severity, alters tissue 
structure and function, leading to cirrhosis and liver failure. Efforts to modulate the 
fibrogenesis process have focused on understanding the biology of the heterogeneous 
liver fibroblast populations.  The fibroblasts are derived from sources within and out with 
the liver. Fibroblasts expressing α-smooth muscle actin (myofibroblasts) may be derived 
from the trans-differentiation of quiescent hepatic stellate cells.  Other fibroblasts emerge 
from the portal tracts within the liver.  At least a proportion of these cells in diseased liver 
originate from the bone marrow.  In addition, fibrogenic fibroblasts may also be 
generated through liver epithelial (hepatocyte and biliary epithelial cell) - mesenchymal 
transition.  Whatever their origin, it is clear that fibrogenic fibroblast activity is sensitive 
to (and may be active in) the cytokine and chemokine profiles of liver-resident leukocytes 
such as macrophages.  They may also be a component driving the regeneration of tissue.  
Understanding the complex inter-cellular interactions regulating liver fibrogenesis is of 
increasing importance in view of predicted increases in chronic liver disease and the 
current paucity of effective therapies. 
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INTRODUCTION 
 
The adult human liver typically weighs around 1.5 kg.  It is the largest internal organ and 
plays many pivotal roles in intermediary metabolism and in the metabolism and clearance 
of xenobiotics.  The liver is responsible for the disposal of bile pigments and for the 
generation of bile acids that are central to the maintenance of cholesterol homeostasis and 
the absorption of dietary lipid from the intestine. The liver also plays an important role in 
lipoprotein metabolism and cholesterol homeostasis. It is the site of synthesis for major 
serum proteins including albumin, complement and clotting factors, and of catabolism of 
amino acids and the generation of urea.  In the normal state the liver is maintained at a 
size which provides substantial over capacity. It also has a remarkable ability to 
regenerate in response to functional parenchymal loss and can return to normal size and 
functional state even after 70% of the parenchyma is lost.  
Chronic liver injury, irrespective of cause, is generally associated with the 
accumulation of matrix proteins – a process referred to as fibrosis.  In parallel with this 
there is a continued stimulus for regeneration leading to further distortion of the hepatic 
architecture and vascular structures (portal veins, hepatic veins). This results in a 
transformation to a nodular architecture, so-called cirrhosis (Figure 1). Given the normal 
functional over capacity of the liver, patients with cirrhosis can have apparently normal 
(compensated) liver function for long periods of time but with many there is ultimately 
decompensation with catastrophic effects on the various strands of intermediary 
metabolism referred to above. In addition the altered vasculature leads to the 
development of portal hypertension. To date most therapies for chronic liver disease have 
targeted the aetiological agent, for example, there are now several effective antiviral 
agents for the treatment of hepatitis B and C. Similarly there are a number of 
immunosuppressive agents that can be given for immune driven processes such as 
autoimmune hepatitis. While these agents often have a beneficial effect on the degree of 
fibrosis there are currently few agents that are specifically developed to interfere with 
fibrosis per se.  For some patients with end-stage liver disease the only available option 
for treatment is orthotopic transplantation. 
 This article will review our current understanding of fibrosis, the experimental 
models available for its study and the potential therapeutic options currently being 
examined. 
 
CLINICAL PERSPECTIVE 
 
Accidental (e.g. adverse reaction to a normally therapeutic drug dose [1]) or deliberate 
(e.g. paracetamol overdose [2]) poisoning can lead to massive liver necrosis, acute liver 
failure and death.  However, chronic liver damage and its associated progressive fibrosis 
is quantitatively a more significant clinical problem [3].  Table 1 outlines the major 
causes of chronic liver disease in the human population.  Viral infections are currently the 
major global cause of liver fibrosis. However, alcohol abuse is another important cause of 
chronic liver disease. Furthermore over the past 25 years it has become increasingly 
apparent that a similar spectrum to that observed with alcohol can be seen in individuals 
who are obese and/or diabetic. This so-called non-alcoholic fatty liver disease (NAFLD) 
can lead to end-stage liver injury and cirrhosis.  The long term socioeconomic impact of 
the “epidemic” of NAFLD and obesity is yet to be established. 
  
LIVER STRUCTURE 
 
Liver tissue is composed of functional units that contain all the cells of the liver arranged 
around point(s) of entry (portal tract – PT) and exit (central veins – CV) of blood.  There 
remains a debate about the structure of the functional hepatic unit with several models 
proposed.  In part, this is because there is no impermeable barrier between the units in 
most species, including humans and rodents.  A review of the various proposed functional 
units is beyond the scope of this review (for more information see [4]) however, the most 
favoured in their simplest terms are referred to here as the liver lobule (first proposed by 
Kiernan) and the liver acinus of Rappaport (see Figure 2A and B).   Zonal expression of 
many genes fits with a lobular functional structure for the liver.  However, the acinus is 
the unit of choice for histopathologists because it aids in the explanation of many 
pathological lesions (Figure 2C).   
The liver receives a dual blood supply; there is a portal circulation which brings 
partially oxygenated blood from the gut, rich in compounds absorbed following digestion. 
In addition some 30% of the hepatic blood comes via the hepatic artery. The two blood 
inputs become mixed at the edge of the portal tracts where the liver sinusoids are found. 
These in essence are the liver’s capillaries and are lined by specialised fenestrated 
endothelial cells, controlling the flow of materials to and from the space between 
hepatocytes and endothelial cells (space of Disse)[5].  The space of Disse contains a low 
density of extracellular matrix proteins and the hepatic stellate cell.  Hepatocytes 
constitute the major epithelial cell type of the liver and extend along the sinusoids to the 
centrilobular region (lobule) or zone 3 (acini) as polarised epithelial cells.  Liver 
macrophages (Kupffer cells) reside within the sinusoids.  The major cell types of the liver 
and their functions are summarised in Table 2.   
A striking feature of the liver is the heterogeneous expression of many genes 
along the sinusoid.  A classic example is the expression of cytochromes P450 genes 
which are expressed at their highest levels in hepatocytes surrounding central veins [6] 
(see also Figure 2B).  Xenobiotics requiring metabolism by cytochrome P450 cause 
predominantly centrilobular / zone 3 damage despite the fact that periportal / zone 1 
hepatocytes are exposed first to ingested xenobiotics.  The majority of exposure to toxins 
is through ingestion of pro-toxins that require enzyme-mediated conversion to a cytotoxic 
product (many directly cytotoxic substances are obviously avoided).  Thus, pro-toxin 
damage is located in the regions where the activating enzyme is expressed.  Additionally, 
oxygen levels are also at their lowest in the centrilobular / zone 3 regions, which may 
impact on the ability of cells to respond to and survive injury.  Hepatocytes are therefore 
more often the cell that is damaged by hepatotoxins (though they are not intrinsically 
sensitive and have a number of active defence mechanisms, such as a capacity to 
maintain high levels of reduced glutathione to defend against oxidative stress [7]).   
 Enzyme-mediated toxicity has particular relevance to acute mechanisms of 
xenobiotic hepatotoxicity but is the cause of only a minor proportion of chronic liver 
disease cases.  Indeed, the major chemically-induced cause of liver disease - alcohol - 
induces changes in gut permeability to bacterial membrane components leading to a pro-
inflammatory hepatic environment as a major part of its mechanisms of action [8,9].  
Most experimental models of fibrosis employ pro-toxin / enzyme-mediated mechanisms 
to cause liver damage.  An understanding of how toxins work in experimental models of 
fibrosis is therefore essential to avoid misinterpretation of data, particularly when the 
efficacy of a potential anti-fibrogenic is being examined. 
 
CURRENT VIEWS OF LIVER FIBROGENESIS 
 
Fibrogenesis is predominantly viewed as a repercussion of the wound healing response 
that occurs after persistent liver tissue damage.  These events are therefore discussed (see 
also Figure 3 and ANIMATION 1).   
Liver injury and the inflammatory response.  In most cases of acute liver injury, 
hepatocytes are damaged and undergo both necrosis and apoptosis.  Figure 2C 
demonstrates the typical effects observed shortly after treatment with the hepatotoxin 
CCl4.  Hepatocytes located mainly around the central veins are damaged because CCl4 is 
a pro-toxin that requires metabolism by cytochrome P450 for toxicity (mainly by CYP2E 
[10], see Table 4).  Cell death is primarily via necrosis although a proportion of 
hepatocytes may undergo an apoptotic mechanism of cell death, particularly following 
chronic exposure [11].  Kupffer cells in damaged areas detect the release of intracellular 
contents and/or apoptotic cells and release a range of cytokines and chemokines that 
activate local resident leukocytes and promote the recruitment of circulating leukocytes to 
the region of damage [12, 13].  Sinusoidal endothelial cells play a complementary role in 
this process through changes in the expression of adhesion proteins that promote the 
tethering of passing leukocytes leading to their trans-endothelial migration to the site of 
injury [14].  Major factors contributing to fibrogenesis include cytokines, many of which 
are released from Kupffer cells but some of which are dervied from myofibroblasts 
themselves (see Table 3).  
 The response to tissue damage and infection is therefore analogous, with 
activation of the innate immune system and the potential activation of the adaptive 
immune system.  In some cases, the latter is followed by a breakdown in tolerance to self 
antigens and therefore to the generation of T cells and antibodies to self antigens [15,16].  
In cases where liver damage is drug-induced, it is probable that the drug and/or a 
metabolite(s) reacts with a protein(s) which is then seen by the immune system as 
foreign.  Once the drug and neo-antigen are cleared, immune tolerance to un-modified 
protein is lost, resulting in continued attack of the self antigen and a chronic autoimmune 
hepatitis.  Typically antibodies to smooth muscle proteins and/or a nuclear antigen are 
detected in affected individuals (in type 1 autoimmune hepatitis) or to microsomal 
xenobiotic metabolising enzymes such as cytochrome P450s (in type 2 autoimmune 
hepatitis) [16].  Ticrynafen (tienillic acid) is metabolised to a metabolite which reacts 
with the generating enzyme (cytochrome P450 2C9), to which antibodies are generated 
[17,18]. 
The inflammation associated with hepatic injury forms part of a regulated 
response to cell damage resulting in the removal of necrotic material.  The liver - 
presumably because of its precarious function as a protector from endobiotics and 
ingested xenobiotics - has evolved the ability to regenerate [19].  The cytokines involved 
in marshalling the inflammatory response to tissue damage, also play an important role in 
the replacement of hepatocytes.  Cytokines - such as tumour necrosis factor α (TNFα) and 
interleukin 6 (Il-6) - prime remaining hepatocytes to be responsive to growth factors such 
as hepatocyte growth factor (HGF) and epidermal growth factor (EGF) [19].  The 
stimulus for liver growth appears to be through a sense of its own functional output.  The 
surgical removal of part of the liver (partial hepatectomy) in which there may be 
relatively minimal cell death, results in regeneration of the remaining liver to the required 
size, as if responding to the rise in the levels of a factor normally metabolised by the 
liver.  This factor may be serotonin [20,21], which is primarily synthesised by the gut and 
would therefore directly pass to the liver via the hepatic portal vein. 
Hepatocyte regeneration in most diseased states therefore comes from existing 
viable hepatocyte mitosis [19].  Recent work suggesting that hepatocytes can be derived 
from the bone marrow [22,23] has now been shown at best, to be a rare event (the 
presence of donor genetic material in recipient hepatocytes is now thought to occur via 
donor bone marrow-derived macrophage fusion with recipient hepatocytes [24,25]).  
Liver-resident leukocytes (e.g. Kupffer cells) are derived from the bone marrow in 
addition to a proportion of other non-parenchymal liver cells [26,27].  An hepatocyte / 
bile duct epithelial cell progenitor cell - termed oval cells in some species – is present in 
portal tract regions (at the level of the so-called “canal of Hering”) but only gives rise to 
hepatocytes when existing hepatocytes are prevented from replicating [28,29].  In this 
respect, the "streaming" hypothesis in which hepatocytes are normally replenished 
(potentially from an oval cell progenitor) from replication in the periportal region [30], 
which could replace hepatocytes after acute centrilobular injury, is not now widely 
accepted [31,32].  Many of the factors which drive the innate immune system to clear 
away the damage also act in an apparent co-ordinate fashion to prime hepatocyte renewal.  
A less well understood component of this process is the re-modelling of the extracellular 
matrix that occurs in damaged parenchyma.    An additional factor however, is that 
myofibroblasts may be essential for effective liver regeneration.  Plasminogen (Plg)-
deficient mice spontaneously develop liver fibrosis [33].  The nuerotrophin receptor – 
p75NTR is expressed in myofibroblasts and appears to function in the trans-differentiation 
from hepatic stellate cells [34].  Plg-/- p75NTR-/- mice have exacerbated pathology 
compared to Plg-/- p75NTR+/+ mice due to inhibited hepatocyte proliferation [34]. 
 (Myo)Fibroblast proliferation.  Fibroblasts were hitherto considered to be a 
relatively inert "space filling" cell type secreting extracellular matrix proteins.  However, 
there is increasing evidence in the liver to suggest that they play a role in tissue 
regeneration; they are now known to express a range of cytokines and chemokines [35-
38].  In generic terms, a population of fibroblast-like cells is activated by (or activation is 
significantly enhanced by) the release of cytokines and reactive oxygen species from 
Kupffer cells and other leukocytes [39-41], to proliferate, secrete proteases, extracellular 
matrix proteins and other factors.  In the acute setting and under some chronic conditions 
in which fibrosis may be reversible, the fibroblast-like cells undergo apoptosis and 
Kupffer cells release factors which remodel the extracellular matrix through secretion of 
matrix metalloproteinases [42,43].  The end result is that the liver sinusoidal structure 
returns to normal and the current theory is that the process of fibroblast-like cell 
activation is an essential component of this process, though this remains to be 
experimentally tested.  
If damage to the liver persists, either continuously or through repeated acute 
episodes within a timeframe such that resolution has not had a chance to occur, fibroblast 
numbers increase and fibrosis develops [ANIMATION 2].  As the liver disease 
progresses, the scarring becomes more extensive, impeding hepatocyte regeneration and 
the function of the organ is compromised.  For a period of time, fibrosis remains 
reversible if the primary cause of liver damage is removed or supressed [44,45].   
 Early work on liver fibrosis originally proposed that hepatocytes were responsible 
for the production of scarring extracellular matrix protein in liver fibrosis [46].  It was 
subsequently shown that hepatic stellate cells were a major source [47,48].  In a normal 
liver, the cells are referred to as “quiescent” and function to store much of the body's 
vitamin A [49].  Hepatocytes esterify vitamin A with fatty acids which are then stored by 
quiescent hepatic stellate cells [49,50].  In response to liver damage, quiescent hepatic 
stellate cells lose their vitamin A and trans-differentiate into a myofibroblast phenotype 
expressing α-smooth muscle actin [51-53], an actin isoform restricted to smooth muscle 
cells.   
 Heterogeneity of hepatic stellate cell-derived myofibroblasts.  In the appropriate 
in vitro culture conditions (see below) quiescent hepatic stellate cells undergo a 
phenotypically similar process of trans-differentiation to myofibroblasts as that which 
occurs in vivo in response to liver damage [54]. It has recently emerged that quiescent 
hepatic stellate cells are not the only fibrogenic cell in the liver.  Quiescent hepatic 
stellate cells can be found in the centrilobular and peri-sinusoidal regions of the liver 
lobule (see Figure 4).  Injury to the centrilobular region (e.g. in alcoholic liver disease) 
results in their activation.  However, Ramadori [55] first suggested that portal tract 
fibroblasts rather than stellate cells were predominantly responsible for fibrogenesis in 
cases where damage was located in the periportal regions of the liver lobule (e.g. 
cholestasis), a view that is now broadly accepted [56-58].   Figure 5 compares the fibrosis 
that occurs in rats treated with CCl4 (a centrilobular hepatotoxin) and bile duct ligation, 
which preferentially damages hepatocytes in the periportal region of the lobule.  Both 
injuries result in fibrosis but extensive α-smooth muscle actin myofibroblast 
immunostaining is only seen in the former with cells positive for vimentin in the latter.  
Thus, it is probable that a different population of vimentin-positive hepatic fibroblasts 
located in the periportal region is responsible for fibrogenesis in cases where periportal 
damage occurs.  However, with more extensive injury the disease progresses, and 
populations of cells from other regions likely contribute to fibrogenesis. 
The complexity of establishing liver myofibroblast identity is compounded by the 
fact that each population of hepatic fibroblasts may be heterogeneous in their expression 
of fibrotic marker genes (and potentially other genes).  In an elegant study from Brenner 
and co-workers, transgenic mice were generated in which red and green fluorescent 
protein reporter gene expression were driven by the α-smooth muscle actin and collagen 
IA1 promoters respectively [59].  Both reporter genes were expressed in culture-activated 
hepatic stellate cells but they were not co-expressed in all cells.  In bile duct ligated mice, 
pericentral and perisinusoidal myofibroblasts were both α smooth muscle actin and 
collagen IA1 marker gene positive whereas periportal fibroblasts only expressed the 
collagen IA1 reporter gene. 
The embryological origin of hepatic stellate cells and liver myofibroblasts.  
Establishing the embryological origin of hepatic stellate cells (i.e. the germ layer from 
which the cells are derived) is complicated by their apparent heterogeneity as a 
myofibroblast.  To date, it has not been formally determined.  Given that adipose, smooth 
muscle cells and fibroblasts are derived from the mesoderm and that stellate cells are 
lipid storing cells with an ability to trans-differentiate into myofibroblasts, it is likely that 
at least a proportion of both hepatic stellate cells (and myofibroblasts) and liver 
fibroblasts are mesodermal in embryological origin.  However, hepatic stellate cells and 
liver myofibroblasts express several genes normally associated with neural tissue, such as 
synaptophysin, nestin and glial fibrillary acidic protein [60].  This supports the possibility 
that hepatic stellate cells (or a proportion of them) have an ectodermal origin, perhaps 
from the neural crest given its ability to generate a range of mesenchymal-like cells [61].  
However, this has recently been tested in transgenic mice.  A transgenic mouse 
expressing the Cre recombinase transgene under control of a WNT-1 promoter /enhancer 
sequence (specific to neural crest cells) was crossed with a transgenic for a fluorescent 
protein whose expression was dependent on removal of a lox P-flanked stop cassette by 
Cre recombinase [264].  Although fluorescent protein was found in all tissues known to 
be derived from the neural crest, there was no expression in desmin positive 
perisinusoidal cells of the liver [264].  This suggests that hepatic stellate cells are not 
derived from neural crest cells. 
In the adult mouse, recent work suggests that some hepatic stellate cells are 
derived from the bone marrow.  When bone marrow cells expressing green fluorescent 
protein (GFP) were transplanted into normal mice, hepatic stellate cells in the recipient 
mice were found to express GFP.  In culture, the GFP-positive stellate cells trans-
differentiated into α smooth muscle actin positive myofibroblasts [62].  In CCl4-treated 
fibrotic animals, GFP also co-localised with α smooth muscle actin [62].  This 
observation has been confirmed in irradiated female mice receiving bone marrow from 
male donor mice.  Myofibroblasts containing a Y chromosome were detected in 
approximately two thirds of recipient fibrotic liver myofibroblasts with little evidence of 
cell fusion [27].  More recently, the scar producing cells associated with bile duct ligation 
(periportal myofibroblasts) have also been shown to originate from the bone marrow in 
an animal model but yet remain distinct from hepatic stellate cells in that they are CD45 
positive [63].  Examination of human liver sections from non sex-matched recipients of 
either bone marrow or liver transplants confirmed that bone marrow contributed to 
myofibroblast populations in patients who subsequently developed liver disease [64].   
These data suggest that hepatic stellate cells and liver fibroblasts at least in part 
originate from a mesenchymal stem cell within the bone marrow in the liver disease state.  
However, there remain a number of observations which suggest that there are other 
sources from which fibrogenic cells may be generated.  For example, Zeisberg et al. 
reported that liver fibroblasts are derived from hepatocytes in vivo during fibrosis through 
an “epithelial to mesenchymal transition”, although most of these fibroblasts were not α-
smooth muscle actin positive [65].  Similarly, Roberstson et al., have shown biliary 
epithelial cell “epithelial to mesenchymal transition” in a patient with primary biliary 
cirrhosis, which may account for the bile ductopenia and portal tract fibrosis that occurs 
with this disease [66]. 
There is an increasing body of literature concerning the plasticity of cells from 
several tissues which have normally been considered mature and terminally 
differentiated.  In this respect quiescent hepatic stellate cells (specifically the proportion 
that are CD133 positive) have been proposed as a progenitor cell not just for liver 
myofibroblasts but for hepatocytes and endothelial cells [67].  Mesenchymal stem cells 
from the adult bone marrow have also been stimulated to form multiple cells types 
(including hepatocytes) in vitro [68,69].  However, it is possible that the in vitro 
environment imparts an unusually potent plasticity to many cells that enable them to 
differentiate in a way that would not occur in vivo (since bone marrow cells do not 
differentiate into hepatocytes appreciably in vivo [23,24]).   
Pivotal role for Kupffer cells in fibrogenesis.  Although the status of hepatic 
myofibroblasts (their number and degree of activation) may directly control fibrosis 
severity, increasing attention is now been given to the role of other cells in the process.  
Macrophages within the liver or monocytes / macrophages recruited to the tissue are now 
known to exert a considerable influence.  Their number increases in damaged liver and 
they are principally located around the regions of damage and fibrosis (Figure 6). 
Thurman’s group showed that inhibition of Kupffer cell function (using 
gadolinium chloride), reduced fibrosis in a CCl4 model of liver fibrosis [70].  More 
recently, Duffield et al, using a transgenic mouse model in which CD11b positive cells 
can be conditionally stimulated to undergo cell death, have shown that liver-resident 
monocytes and macrophages not only promote fibrogenesis, but that they are 
instrumental in the removal of fibrosis during any recovery phase[71]. 
The promotion of fibrogenesis by Kupffer cells is associated with the release of a 
range of pro-fibrogenic cytokines and reactive oxygen species as part of their 
inflammatory response to liver damage.  It is notable that the presence of Kupffer cells 
(normally present in low numbers in most isolations) in hepatic stellate cell cultures 
promotes a myofibroblast phenotype closely similar to the cells in vivo [54].  But 
macrophages – in response to the milieu of cytokines and other factors – respond by 
releasing different mixtures of cytokines.  It may be appropriate to suggest that 
macrophages differentiate into a variety of states.  With regard to recovery from fibrosis, 
macrophages may differentiate into an anti-inflammatory phenotype and/or secrete 
proteinases that promote the degradation of scarring extracellular matrix proteins.  
 
RESEARCH MODELS OF LIVER FIBROSIS 
 
 In vivo models of liver fibrosis.  In view of the complex inter-cellular 
communication between cell types within the liver, and that extrahepatic cells may 
contribute to fibrogenesis, animal models remain an important experimental tool.  In 
studies where the aim is to test the efficacy of a potential anti-fibrogenic, it is generally 
considered that drugs should be tested in at least 2 animal models (where the region of 
lobular damage is different so that effects on hepatic myofibroblasts derived from 
different regions of the lobule can be determined).  Table 4 summarises animal models of 
liver fibrosis most commonly employed.  A vital issue with regard to the use of these 
models is that their use should be carefully matched to the mode of action of potential 
anti-fibrogenics.  It is clear that treating the primary cause of liver damage in the human 
population would be the mode of therapeutic choice when available.  The use of a 
potential anti-fibrogenic would be indicated when the primary cause of liver damage 
cannot be treated and/or fibrosis has progressed to cirrhosis.  Accordingly, it is essential 
to ensure that the potential anti-fibrogenic does not modulate the hepatotoxicity of the 
experimental agent used to generate liver damage (i.e. that a potential anti-fibrogenic was 
not a CYP2E inhibitor if using the CCl4 model of liver fibrosis [72]) when using an 
animal model.  Reductions in fibrosis could therefore be associated with reduced levels of 
liver damage, and not due to an anti-fibrogenic action. Commonly used markers of liver 
fibrosis are given in Table 5. 
  While the various animal models hitherto developed have served an important 
function in identifying basic mechanisms of liver fibrogenesis and testing new anti-
fibrotic agents, it must be appreciated that all show some significant morphological 
differences with their human “counterparts”. This is perhaps least so with cholestatic 
models, in particular common bile duct ligation where the pattern of fibrosis is very 
similar to that seen when there is interruption of bile flow in man. On the other hand the 
commonly used CCl4 model is probably the most frequently used tool for investigating 
regression of fibrosis and cirrhosis but the fibrous septa observed in animals - even on 
long term CCl4 - are generally much less developed compared to most human cirrhoses. 
Probably one of the most important differences between human and animal model disease 
is the lack of significant alteration of vascular relationships in the latter; human cirrhosis 
is often confounded by liver cell loss through secondary hypoxic events leading to 
parenchymal extinction. This does not occur in the commonly used animal models. 
In vitro models of liver fibrosis.  The most commonly used in vitro model of liver 
fibrosis is the isolation of quiescent hepatic stellate cells and their culture on plastic 
culture dishes in serum-containing culture media.  Under these conditions, cells 
commence a phenotypically similar process of trans-differentiation to the activated 
myofibroblast phenotype apparent in the liver in response to chronic liver damage (see 
Figure 7), particularly when Kupffer cells are present (as a minor impurity) within the 
culture [54].   The cells are amenable to trypsin sub-culture although once the cells have 
activated to a myofibroblast phenotype, the cells remain in the myofibroblast phenotype 
in subsequent passages.  Where possible, cells should be used in primary culture since 
this period is the only time to examine effects on trans-differentiation. 
There is a concern that differences in laboratory protocols may result in 
differences in the nature of hepatic myofibroblasts, and that hepatic stellate cell-derived 
myofibroblasts may be overgrown by portal tract myofibroblasts [55-57].  Indeed, at 
present there is no universally agreed diagnostic marker for quiescent hepatic stellate cell 
populations that could be used to establish cell identity and purity.  Nevertheless the in 
vitro culture system will remain a valuable tool for studying liver fibrosis and can readily 
be used in high throughput screening assays for potential anti-fibrogenics. 
A technically more challenging in vitro model is the culture of liver slices  
[73,74].  Liver slices from normal or diseased liver will retain their native extracellular 
matrix, cell-cell contacts and cell density and may be a valuable model for short term 
studies.  However, even the thinnest tissue slices (~200µm thick, ~ 10 cells thick) prevent 
effective access of nutrients to cells and a large proportion of the slice, particularly 
hepatocytes, die after 24 hours [75,76].   
Hepatic stellate cells from rodents are readily sub-cultured for many passages and 
therefore - for studies using myofibroblasts in their pro-fibrogenic state only – 
immortalised cell lines are often not required.  To study the process of trans-
differentiation from the quiescent state, cells must be repeatedly isolated from animals as 
myofibroblasts do not readily revert to the quiescent state.  The value of a rodent hepatic 
stellate cell line (see Table 6) lies with their propensity for being transfected with plasmid 
constructs because cells isolated from rodents are difficult to transfect with high 
efficiency.  Human hepatic stellate cell lines are more common because of difficulties in 
most laboratories of accessing human tissue.  Further, in our hands, most human 
myofibroblast cultures appear to senesce at passage 2 – 5 (from 58 human preparations, 
only 2 cultures have remained proliferative from more than 5 passages).  This may be due 
to isolation of cells from primarily elderly patients (mainly from partial hepatectomy 
specimens from individuals with a secondary tumour in the liver).  Human 
myofibroblasts are also resistant to transfection and in our hands only nucleofection was 
sufficiently effective (with repeatable high efficiency) for the transfection of a range of 
reporter gene plasmid constructs [38].  Viral vectors have therefore been investigated 
from time to time for their ability to infect cells with high efficiency, including adenoviral 
[77,78], retroviral [79] and baculoviral [80].  Although reported to be effective, the 
resources required to generate recombinant vectors has probably contributed to their lack 
of widespread use. 
The in vitro model systems outlined above remain an effective way to screen a 
large number of potential compounds at an early stage for their ability to modulate the 
fibrogenic process using a variety of endpoints.  However, as with many in vitro systems, 
there are limitations that prevent the identification of anti-fibrogenics with 100% 
accuracy.  In vitro systems are closed artificial units that cannot allow for the absorption, 
distribution, metabolism and excretion of drugs that you see in whole body studies.  Liver 
myofibroblasts also reside next to the major drug metabolising cell of the body in vivo, 
but these are arguably functionally absent from most in vitro systems.  Thus, the 
replacement of in vivo animal models with in vitro models has yet to be achieved and the 
former will probably always have a role to play in studies of liver fibrosis. 
 
CLINICAL TREATMENTS FOR LIVER FIBROSIS 
 
A number of reviews have appeared recently on approaches to the treatment of liver 
fibrosis [82-84] and so only brief discussion is given here.  Currently there is no 
therapeutic agent indicated and licensed for the primary treatment of liver fibrosis 
although a number of therapies are in clinical trials (Table 7).  A variety of potential drug 
targets have been shown to exist within hepatic myofibroblasts in experimental systems 
but many of these are associated with other cell types which presents problems of drug 
specificity.  Indeed, the surprisingly varied number of targets available suggests there 
may be redundancy for each pathway in myofibroblasts.  Thus, the drug-mediated block 
of a pathway promoting fibrogenesis may be overcome by the remaining unrelated 
fibrogenesis-promoting pathways.  For these reasons and because myofibroblasts produce 
a number of factors which act in an autocrine fashion to promote fibrogenesis, the 
efficacy of drug treatments that lead to myofibroblast apoptosis have been examined 
[84,85]. 
In animal models recovering from chronic liver damage (i.e. the cause of damage 
is stopped), fibrosis reversal is associated with the apoptosis of liver myofibroblasts [44].  
NF-κB is a transcription factor that regulates the expression of a range of genes 
associated with inflammation [86].  NF-κB becomes constitutively active in 
myofibroblasts in vitro and induces the expression of several pro-inflammatory genes 
(e.g. ICAM, nitric oxide synthase 2) [87].  NF-κB is also constitutively active in 
myofibroblasts in vivo, suggesting that it is not an artefact of the in vitro culture system 
[88].  NF-κB functions to prevent the apoptosis of myofibroblasts [84,87] as it does in 
other cells (e.g. hepatocytes) when they exposed to pro-inflammatory mediators such as 
TNFα [89,90].  Inhibition of NF-κB therefore leads to the apoptosis of myofibroblasts in 
vitro [87] and in vivo [84,85].   The stimulation of liver myofibroblast apoptosis using 
gliotoxin (a fungal toxin that inhibits NF-κB [91], but which also works directly on the 
mitochondria to promote apoptosis [92]) resulted in a rapid recovery from fibrosis and 
using this compund provided the first evidence in vivo that myofibroblast apoptosis may 
be an effective therapeutic approach to liver fibrosis treatment [84].  Using existing 
licensed NF-κB inhibitor drugs such as sulphasalazine to acheive the same ends may be a 
realistic treatment option [85].  More recently, targeting gliotoxin to hepatic 
myofibroblasts using a recombinant single chain antibody to a surface antigen on the cells 
(thereby retaining functional liver macrophages), reduced fibrosis in vivo in a sustained 
injury model in contrast to free gliotoxin [93].  The specific removal of liver 
myofibroblasts in a “non-inflammatory” manner whilst leaving macrophages in place, 
therefore appears to be an effective anti-fibrogenic approach.  By removing the liver 
myofibroblasts, the potential of specific drug targets within these cells becoming 
redundant with time is avoided.  The converse however is that employing cell death 
mechanisms as a therapeutic approach requires careful targeting to avoid adverse effects.  
Further, it remains to be seen whether myofibroblast reductions as part of an anti-
fibrogenic approach has any deleterious effects on liver regeneration. 
Treatments in which drug targets have opposite effects in hepatocytes and liver 
myofibroblasts may turn out to be safer options, particularly when disease progression is 
to be slowed (in contrast to stimulating a reversal of cirrhosis).  The pregnane x receptor 
(PXR) is a nuclear receptor transcription factor that regulates the expression of genes 
associated with endobiotic and xenobiotic clearance in hepatocytes [94].  PXR function is 
normally activated through contact with a range of ligands, including existing licensed 
drugs (e.g rifampicin) and endogenous compounds (steroids, bile acids) [94].  Recent 
work from this laboratory has shown that the PXR is expressed in myofibroblasts, is 
capable of binding to its DNA enhancer response element in myofibroblast nuclear 
extracts and is transcriptionally functional on transfected reporter gene constructs [38].  
The PXR regulates a specific set of genes in myofibroblasts.  Ligand activators of the 
PXR reduce the expression of pro-fibrogenic cytokines such as TGF-β and inhibit 
proliferation [38].  PXR activators therefore act in an anti-fibrogenic manner in human 
liver myofibroblasts in vitro [38].  Using mice with a disrupted PXR gene, the role of the 
PXR in mediating an anti-fibrogenic effect was unequivocally established [72].   
 
CONCLUSIONS 
The fibrotic response in the liver is dependent on multiple cell types, both resident and 
recruited to the liver, and is regulated by a vast array of factors in vivo.  A full 
understanding of the response remains a goal at present, in particular, the benefit of 
fibrosis to tissue function and viability.  The ability to specifically “knock-out” cell types 
in a tissue should help to resolve many questions in the same way that transgenic 
technology has resolved questions surrounding a specific gene’s function.  Clinically 
employed anti-fibrogenics may then become available. 
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Figure titles and legends. 
 
Figure 1.  Appearance of a cirrhotic liver.  Scale is in cm.   
 
Figure 2.  Commonly used liver unit structures and their relationship to liver 
damage.  A, Schematic diagrams of the hepatic lobule of Kiernan (upper ) and liver 
acinus of Rappaport (lower).  The position of the lobule has been superimposed onto the 
acinus to aid in their comparison.  Note that in the lobular model, blood from the portal 
tract (PT) containing a periportal venule (PV) and bile duct (BD) and periportal arteriole 
(PA) may flow into other adjacent lobules with nutrient and oxygen levels falling as 
blood flows from the portal tracts to various central veins (CV).  In contrast, blood 
entering the acinus via the portal tract is thought to remain within the acinar unit, with 
nutrient and oxygen levels falling as the blood flows from zone 1 to 3.  Dye injection 
studies [263] demonstrated that portal tracts should not be considered as terminal afferent 
vasculature since vessels extend and meet and terminate in regions termed the nodal point 
of mall (NPM).  B,  Immunohistochemical staining for CYP2E expression in mouse liver.  
This gene is highly expressed in hepatocytes but it can clearly be seen that expression is 
restricted to hepatocytes surrounding the CV.  C, Haematoxylin and eosin stained liver 
sections from a normal and CCl4-treated mouse.  It can be seen that damage is restricted 
primarily to hepatocytes surrounding the central vein. 
 
Figure 3.  Schematic diagram of the events that occur in the liver in response to 
acute liver damage around the CVs.  A, sequential events from normal structure, 
localised cell death, inflammation and regeneration.  B, key to the various cell types. 
 
Figure 4.  The sources of liver myofibroblasts in the liver.   
 
Figure 5.  Different populations of fibroblasts proliferate in the liver dependent on 
the location of the damage.  Typical views of liver sections from control animals or 
animals after chronic liver injury via repeated CCl4 injection or through ligation of the 
bile duct (BDL).  The stain employed is as indicated. 
 Figure 6.  Macrophages and liver fibrosis.  ED1 (CD68) Immunostain for monocytes, 
macrophages and Kupffer cells in rat liver sections from a control or CCl4-treated rat.  
Right panel, high powered view. 
 
Figure 7.  The trans-differentiation of quiescent hepatic stellate cells to 
myofibroblasts in vitro.  Human hepatic stellate cells were isolated and cultured as 
outlined [38].  Left panel (soon after isolation as cells attach), right panel, after 17 days of 
culture.  Lower panel, Western blot for α-smooth muscle actin expression in cultured 
cells at the indicated time.  Each lane contains 10µg total cell protein. 
 
 
 
Table 1.  Major causes of chronic liver disease  
 
 
Disease 
 
Cause 
 
Incidence 
 
Diagnosis 
 
Treatments 
Additional 
comments 
Infectious Diseases     
Hepatitis B dsDNA virus (HBV).  Passed 
through infected body fluids 
[95]. 
Estimates of 350 million 
people infected worldwide 
[96]. 
ELISAs to detect antibody to 
viral antigens*.  PCR may also 
be used to check for the 
presence of the virus. 
Vaccination available.  Patient 
may be monitored to see if 
virus is cleared.  If not, anti-
viral therapy may be used 
(interferon-α and nucleoside 
analogue therapies [97]). 
 
Hepatitis C ssRNA virus (HCV).  Passed 
through infected body fluids 
[98]. 
Estimated 170 million chronic 
carriers worldwide [99]. 
PCR is used to check for the 
presence of the virus.  ELISAs 
also available. 
No vaccine available.  Patient 
may be monitored to see if 
virus cleared with anti-viral 
therapy (interferon-α and 
nucleoside analogue therapies 
[100]. 
Around a third of patients clear  
the virus without treatment.  A 
third respond to treatment.  The 
remainder  become chronically 
infected and develop fibrosis and 
cirrhosis [101]. 
Hepatitis D Ss RNA virus (HDV).  Passed 
through infected body fluids 
[102]. 
 
A proportion of HBV infected 
individuals will also be 
positive for HDV  [103]). 
ELISAs to detect antibody to 
viral antigens.  PCR may also 
be used to check for the 
presence of the virus. 
HBV vaccination.  As for 
HBV. 
HDV requires co-infection with 
HBV for it to be replicated [104]. 
Auto-immune diseases     
Primary biliary 
cirrhosis 
Immune- mediated attack of 
the small  intrahepatic bile 
ducts.  Unknown cause - may 
be triggered by an infection or 
chemical exposure [105].  
1:700 women (Western 
populations), disease 10 times 
more common in women over 
men [106]. 
Presence of “anti-
mitochondrial antibodies” 
(AMA) primarily to the E2 
sub-unit of the  pyruvate 
dehydrogenase complex [107]. 
No curative treatment - 
symptoms and potentially 
disease progression treated 
with ursodeoxycholic acid 
[105].   
Therapeutic agents that either 
replace endogenous more toxic 
bile acids (ursodeoxycholic acid 
[108]) and/or increase bile acid 
metabolism through induction of 
cytochrome P450 3A [109] 
(although this is disputed [110]) 
and/or inhibit fibrogenesis 
[38,72].  Potential animal models 
[111-113]. 
Autoimmune 
hepatitis 
Immune-mediated attack of 
hepatocytes [114]. 
Female predominant [114]. Based on a variety of criteria 
with exclusion of other causes 
[115]. 
Glucocorticoids.  Effective but 
long term most progress to 
cirrhosis. 
Type I characterised by antibodies 
to smooth muscle and/or anti-
nuclear antibodies (SMA + 
ANA); Type II by antibodies to 
cytochrome P450s such as 
CYP2D6 (LKM); Others include 
soluble liver antigen , a tRNA 
associated protein [116]. 
Inherited       
Hereditary 
haemachromatosis 
Homozygous mutation in HFE 
gene [117] - body absorbs too 
much iron which is stored in 
the liver - leading to toxicity. 
1:400 – 1:200 of european 
populations [118].  
Iron can be measured in liver 
biopsy specimens for overload.  
Genetic analysis [119]. 
Venesection Other disorders can lead to iron 
accumulation in the liver. 
Wilson's disease Mutations in a P-type copper  1:5000 to 1:30,000 [121]. Measurements of blood levels  Administration of copper  Long Evans Cinnamon rat  
 transporting ATPase gene - 
leads to copper accumulation 
in the liver [120]. 
 of  copper and caeruloplasmin, 
also genetic diagnosis [122]. 
chelating agents (e.g. 
penicillamine) [123]. 
model  [124]. 
Cystic fibrosis 
 
 
Homozygous mutation in the 
cystic fibrosis trans-membrane 
conductance regulator (CTFR) 
[125]. 
1:2500.  Around 30 % suffer 
liver disease [125]. 
Genotyping PCR [126]. Ursodeoxycholate [127]. CTFR gene is expressed in the 
apical membranes of biliary 
epithelial cells of the branching 
hepatic bile ducts [128]. 
Dietary      
NAFLD and Non 
alcoholic 
steatohepatitis 
(NASH) 
Fat accumulation (steatosis) in 
the liver in the absence of 
alcohol consumption.   Obesity 
with an additional damaging 
component such as hepatic 
inflammation is termed NASH. 
Prevalence of up to 30%.  
Associated with obesity.  
NAFLD considered benign in 
the absence of other aetiologies 
[129]. 
Liver biopsy. Weight loss and exercise.  
Drugs used to treat type II 
diabetes are also be considered, 
such as the biguanide 
metformin  [130] and 
thiazolidinedione (PPARγ 
agonists) such as pioglitazone 
[131]. 
NASH likely develops on a 
background of NAFLD via “Two 
hit” theory [132]. 
Chemical      
Alcohol Increased gut permeability to 
endotoxin leading to a pro-
inflammatory liver 
environment. 
Elevation of ROS with hypoxia 
Production of acetaldehyde by 
metabolism (alcohol 
dehydrogenase / CYP2E1). 
Commonest cause of cirrhosis 
in the Western world and one 
of the ten most common causes 
of death [133]. 
Liver biopsy. Abstinence.  Drugs designed to 
ameliorate inflammation in the 
liver include glucocorticoids, 
and drugs which reduce TNFα 
expression or activity [133].  
Coffee consumption is 
associated with reduced liver 
damage with alcohol 
consumption [134]. 
Steatosis and steatohepatitis are 
both features of alcoholic liver 
disease.  
Other      
Gallstones Accumulation of solid material 
/ stones in gall bladder. 
Increases with age – present in 
up to 20% of 60-69 yr olds 
[135]. 
Imaging techniques. Surgery. Blockage of gall bladder outlet or 
bile duct leads to inflammation of 
the bile ducts (cholangitis). 
Budd Chiari 
syndrome 
Obstruction of hepatic venous 
outflow normally due to 
thrombosis. 
1:100,000 [136]  Anti-coagulants. 
Stents to redirect blood flow to 
heart [137]. 
 
Primary 
sclerosing 
cholangitis 
Progressive loss of bile ducts 
due to inflammation.  Cause 
unknown. 
1:100,000 per year, more 
common in males [138]. 
Cholangiography[138]. No curative treatment - 
symptoms treated with agents 
that reduce build up of 
systemic bile acids, e.g. 
ursodeoxycholic acid [138]. 
Often linked with inflammatory 
bowel diseases - particularly 
chronic ulcerative colitis [139]. 
 
 
 
Table 2.  Cell types of the liver. 
 
 
Cell type 
 
Functions 
Useful markers in 
adult liver tissue 
   
Hepatocytes. 
 
 
Most functions of the liver.  
Intermediary metabolism 
Albumin., cytokeratin 8 and 18 [140]. 
Kupffer cells. 
 
 
 
Liver-resident macrophage.  
Phagocytosis of ingested 
pathogens and particles. 
ED-1 (orthologue of human CD68 -  also labels 
monocytes and peripheral macrophages); ED-2 
(orthologue of human CD163 [141]). 
Endothelial cells. 
 
 
Fenestrated endothelial cell lining 
liver sinusoids. 
CD31, vWF [142]. 
Hepatic stellate cell. 
 
 
 
 
Storage of vitamin A, production 
of myofibroblasts in injury. 
Quiescent phenotype – GFAP, desmin in 
experimental animals [143]. 
Myofibroblast phenotype – α smooth muscle actin. 
Biliary epithelial cell. 
 
Line bile ducts. cytokeratin 7, 19 [144,145]. 
Portal tract fibroblast. 
 
Integrity of portal tracts; 
supporting function 
 
vimentin [146]. 
“Oval cells”. 
 
 
 
Bi-potential progenitor cell for 
hepatocytes and biliary epithelial 
cells. 
α-fetoprotein [147], cytokeratin 19 [148], cytokeratin 
8 [147], OV-6 [149]. 
Liver-associated lymphocytes 
(NK (Pit) cells, γδT cells, NKT 
cell) [150]. 
 
Kill infected or tumourigenic 
liver cells. 
CD3 [150]. 
Vascular endothelial cells. 
 
Line blood vessels. CD34, CD31 [151]. 
Lymphatic endothelial cells. 
 
Line lymphatic vessels. Podoplanin [152]. 
 
Table 3.  The major endogenous factors regulating liver fibrogenesis. 
 
 
Factor 
 
Cell source 
Effect on 
fibrosis 
 
Experimental  evidence 
    
IFNα Many cell types. ↓ Pegylated IFNα is used clinically (see table 1) to reduce HBV and HCV viraemia but may also inhibit fibrosis in addition 
[153,154].  In animals, IFNα inhibited liver fibrosis in a CCl4 model but not a bile duct ligation model [155]. 
 
IFNγ Lymphocytes. ↓ IFNγ treatment inhibits hepatic stellate cell activation and fibrogenesis in vitro and in vivo [156,157].  Peripheral blood 
mononuclear cells from HCV patients with low fibrosis had more IFNγ-producing cells than patients with higher fibrosis scores 
[158]. 
 
Il-1β Leucocytes, including Kupffer 
cells. 
↑ An Il-1 receptor antagonist inhibits liver fibrosis in rats [159].  Il-1β induces collagen type 1 expression in liver myofibroblasts in 
vitro [160].  Il-1 induced matrix metalloproteinase expression by quiescent hepatic stellate cells as part of their activation to 
myofibroblasts [161]. 
 
Il-6 Leucocytes, including Kupffer 
cells; myofibroblasts. 
↓ Conditional gp130 (Il-6 receptor protein partner) knockout in liver non-parenchymal cells had no effect on CCl4 toxicity but 
resulted in increased fibrosis in chronic model [162].  Note that Il-6 is pivotal in priming hepatocyte proliferation / regeneration 
[163] and this complicates interpretation of direct Il-6 knock-out effects on liver fibrosis.  Also, other studies have suggested Il-6 
promotes fibrosis but in these studies there was evidence that Il-6 treatment also gave rise to greater levels of liver damage 
[164,165]. 
 
Il-10 Leucocytes, including Kupffer 
cells. 
↓ Reduced liver fibrosis in Il-10-/- mice administered CCl4 without significant effects on toxicity [166,167].  Il-10 treatment led to 
reductions in liver fibrosis in HCV patients (interferon non-responders) [168]. 
 
PDGF Megakaryocytes and Platelets 
in blood.  Expressed by many 
cell types however, including 
Myofibroblasts. 
 
↑ PDGF is the most potent mitogen for hepatic stellate cell-derived myofibroblasts (EGF, TGF-α, and FGF-2 are also mitogens) 
[169].  PDGF levels increase in liver disease [170,171].  Dominant-negative soluble PDGF receptor β inhibits fibrosis [172]. 
 
TGFβ1 Expressed by many cell types, 
including 
Myofibroblasts. 
↑ TGF-β1 transcriptionally up-regulates collagen 1AI in hepatic stellate cells in vitro [173].  Albumin promoter (hepatocyte) over-
expression of TGF-β1 in transgenic mice increases fibrosis in vivo [174].  Soluble TGF-β receptor type II treatment inhibits 
fibrosis in vivo [175].  Adenovirus encoding antisense TGF-β mRNAinhibits fibrogenesis in vivo [176]. 
 
TNFα Leucocytes, including Kuppfer 
cells 
↑ TNFα receptor 1-/- (but not TNFα receptor 2-/-) had reduced fibrosis in CCl4 in vivo model [177].  Note that TNFα receptor 1 also 
primes hepatocyte proliferation / regeneration [178]. 
Many other factors have been shown to modulate fibrosis via a direct role myofibroblasts, including adiponectin [179], angiotensin 
[180], cannabinoids [181,182], leptin [183] and opioids [184]. 
 
Table 4.  In vivo models of liver fibrosis. 
 
Hepatotoxin or 
causative agent 
(typical dose) 
Model 
Species 
System of 
activation  
Acute mechanism of 
damage 
Histological 
lobular 
effects 
Fibrosis Further comments 
Carbon tetrachloride 
(1ml/kg body weight i.p. twice 
weekly from 4 – 12 weeks)  [185]. 
Rat 
Mouse. 
CYP450 – primarily CYP2E1 
[186]. 
Lipid peroxidation [187,188]. Centrilobular hepatocyte 
death [188]. 
Fibrosis emerging from the 
CVs eventually leading to 
central – central bridging 
fibrosis. 
 
Most commonly employed means to generate liver fibrosis 
in animal models.  Primarily α-smooth muscle actin positive 
myofibroblasts. 
Thioacetamide 
(300mg/l  drinking water or 
200mg/kg body weight i.p. 2 – 3 
times per week for upto 12 weeks) 
[189]. 
 
Rat 
Mouse. 
CYP450 – primarily CYP2E1 
[190].  Also FMO [191]. 
Generation of reactive sulfdioxide 
leading to non-specific covalent 
binding of cell constituents [192]. 
Centrilobular hepatocyte 
death [189]. 
Fibrosis emerging from the 
CVs eventually leading to 
central – central bridging 
fibrosis. 
Primarily α-smooth muscle actin positive myofibroblasts. 
Dimethylnitrosamine 
Varied protocols – 10mg/kg body 
weight i.p. 3 consecutive days/week 
for upto 2-4 weeks; single 50mg/kg 
body weight i.p.   Endpoints upto 
10months [193]. 
 
Rat 
(mouse 
[194]). 
CYP450 – primarily CYP2E1 
[195]. 
Metabolism by CYP450 to produced 
reactive formaldehyde -  methylation 
of cell constituents [196].   
Hepatocyte apoptosis [197]. 
Haemorrhagic 
centrilobular necrosis – 
destruction of sinusoidal 
endothelial cells leads to 
coagulation [198]. 
Fibrosis emerging from the 
CVs eventually leading to 
central – central bridging 
fibrosis. 
Haemorrhagic necrosis results in  macrophage phagocytosis 
of eryhthrocytes and necrotic debris which accumulate high 
levels of iron for extended periods after injury. and 
localised high levels of oxidative stress.then retain abundant 
levels of iron [193].   Primarily α-smooth muscle actin 
positive myofibroblasts. 
Pig serum 
0.5ml twice weekly 4 – 16 weeks 
[199]. 
Rat. n/a Portal vein thickening  - 
haemodynamic effects – cell 
damage/apoptosis [200]. 
No overt damage to 
hepatocytes (no increase 
in ALT or ALP [200]). 
Fibrosis emerging from the 
CVs eventually leading to 
central – central bridging 
fibrosis. 
 
Hepatitis likely stimulated – tolerised rats have marked 
reduced fibrosis [201].  Primarily α-smooth muscle actin 
positive myofibroblasts. 
Bile duct ligation 
Surgical procedure in which the bile 
duct is ligated – normally for upto 3 
to 4 weeks [202]. 
 
Rat 
Mouse. 
n/a Raised liver bile acids stimulate 
hepatocyte apoptosis [203,204] and 
at higher levels, necrosis (cell 
membrane disruption [205]). 
Periportal hepatocyte 
death [206]. 
Fibrosis emerging from the 
PT eventually bridging 
fibrosis. 
Primarily vimentin positive myofibroblasts [207,208]. 
Methionine- and choline -deficient 
diet [209].  Upto 12-15 weeks 
[210,211]. 
Rat 
Mouse. 
Choline deficiency  results in 
reduced fatty acid β oxidation and 
reduced triglyceride clearance by 
the liver [209, 212].  Methionine 
deficiency leads to reductions in 
liver glutathione and increases in 
ROS (e.g. via CYP2E1) [209]. 
Lipid accumulates in hepatocytes.  
Oxidative stress results in hepatocyte 
necrosis and inflammation. 
Lipid accumulation 
occurs in the 
centrilobular regions of 
the liver [213].  In 
humans, lipid 
accumulation is in the 
portal tract region [214]. 
Fibrosis. Model of NASH that includes fibrogenesis although mice 
lose weight in contrast to NASH in humans.  Note that in 
the leptin-deficient (ob/ob) mouse there is lipid 
accumulation within the liver but that a “second hit” is 
required to generate inflammation (e.g. administration of 
LPS) [215].  Despite this, little fibrosis is seen in the ob/ob 
mouse, probably because of leptin deficiency [216]. 
 
Alcohol – intragastric enteral 
feeding model [217]. 
Rat 
Mouse. 
Metabolism of alcohol to 
acetaldehyde unlikely to be the 
major mechanism  (in the absence 
of acetaldehyde dehydrogenase 
inhibition (e.g. disulfiram  or 
genetic mutations [218]). 
Increased gut permeability to 
endotoxin resulting in hepatic 
exposure to reactive oxygen species 
and  inflammation [219]. 
Lipid accumulation 
occurs in the 
centrilobular regions of 
the liver.  Inflammation 
and necrosis in the 
centrilobular region at 2 
- 4 weeks [220]. 
 
Liver fibrosis at 8 – 10 
weeks [220]. 
This model enables calorific pair feeding where control 
animals receive the same diet with glucose substituted for 
alcohol.  For other models see [221]. 
Concanavalin A (up to 20mg/kg 
body weight i.v. once/week for up 
to 20 weeks [222]. 
Mouse.  The lectin concanavalin A stimulates 
a cytokine secretion syndrome.  
CD4+ T cells infiltrate the liver. 
Hepatocyte necrosis 
observed only after 
initial treatments.  
Inflammatory infiltrate 
persists, particularly CL 
region. 
CL and perisinusoidal 
fibrosis [223]. 
 
In general, rats generate a more robust fibrosis and/or tolerate more readily liver fibrosis than mice.  However, the utility of transgenic mice in biological research and widespread use and availability of 
mouse transgenics often require the use of mice in studies.   
Table 5.  Commonly used tests and markers for liver fibrosis 
 
 
Marker 
 
Comments 
 
Non invasive tests. 
 
Difussion weight 
MRI 
Measures the apparent diffusion coefficient (ADC) of water.  Assessed for the diagnosis of liver fibrosis in patients with chronic HCV [224]. 
Elastography 
(Fibroscan) 
Ultrasound (5 MHz) and low-frequency (50 Hz) elastic wave detection - propagation velocity through tissues is related to elasticity [225]. 
  
Tests requiring blood analysis. 
APRI Aspartate aminotransferase to platelets ratio index [226]. 
ELF Serum hyaluronic acid, amino-terminal propeptide of type III collagen, and tissue inhibitor of matrix metalloproteinase 1 plus age [227]. 
Fibrometer hyaluronate, prothrombin time, platelets, AST, α2 macroglobulin, urea and age [228]. 
FIBROSpect II hyaluronic acid, tissue inhibitor of metalloproteinases 1, and alpha-2-macroglobulin [229] 
Fibro-Test FibroTest is used for the assessment of fibrosis, ActiTest for the assessment of liver necrosis [230].  The test determines alpha2-
macroglobulin, haptoglobin, gamma glutamyl transpeptidase (GGT), total bilirubin, apolipoprotein A1 and alanine aminotransferase. 
FORNS test Combining age, GGT, cholesterol, and platelet count [231]. 
Hepascore bilirubin, γGT, hyaluronic acid, α2 macroglobulin, age and sex [232]. 
MP3 procollagen type III N-terminal peptide (PIIINP) and matrix metalloproteinases (MMP)-1 [233]. 
 
Test requiring liver tissue.  Routine liver function tests do not give an indication of liver fibrosis severity.  At present, the gold standard for assessing the stage of 
liver disease and direct assessment of fibrosis using a general Haematoxylin and Eosin stain and some of the stains outlined below.  Scoring systems have been 
developed for liver disease severity such as those referred to as METAVIR [234], Scheuer [235], Ishak [236], Knodell [237] systems. 
 
Parameter associated with pro-fibrogenic cell numbers. 
α-Smooth muscle 
actin 
Primarily via immunohistochemical staining – detects myofibroblasts (see Figure 5).  Smooth muscle cells within blood vessels are also 
positive, therefore interpretation required to assess for degree of fibrosis.  Western blotting liver extracts will not distinguish myofibroblast-
associated α-smooth muscle actin. 
Vimentin Primarily via immunohistochemical staining – detects fibroblasts associated with portal tract fibrosis (see Figure 5).   
 
Direct determination of fibrosis. 
Sirius red stain Relatively simple histochemical stain for primarily collagen type I (see Figure 5).  Vessels are positive in normal liver, therefore 
interpretation required to assess for degree of fibrosis.  Also Masson’s Trichrome stain [238]. 
Collagen 1A1 Immunohistochemical staining [239].  Vessels are positive in normal liver, therefore interpretation required to assess for degree of fibrosis. 
Hydroxyproline Collagens have a high proportion of hydroxyproline residues.  Biochemical assay [240] to detect total liver hydroxyproline but high control 
tissue values result in small overall fold changes in fibrotic liver. 
Reticulin Stains collagen type 3, which is highly glycosylated and therefore visible through silver staining techniques [241]. 
Shikata’s Orcein Detects elastic fibres: this is a marker of longstanding fibrosis. 
  
Table 6.  Hepatic stellate cell lines. 
 
 
Cell line 
 
Species 
 
Comments 
   
LX-1. 
 
Human SV40 T antigen immortalised [242]. 
LX-2. 
 
Human [242]. 
LI-90. 
 
Human [243]. 
TWNT-4. 
 
 
Human LI-90 cells with retrovirally induced human telomerase reverse transcriptase 
(hTERT) [244]. 
HSC T6. 
 
rat Clone from cells transfected with the large T-antigen of SV40 [245]. 
PAV1. 
 
rat [246]. 
CFSC-2G. 
 
rat [247]. 
HSC from metallothienein 
+/+
 and -/- mice. 
mouse SV40 virus transformed [248]. 
 
 
Table7.  Recent and current clinical trials for anti-fibrogenics for the liver. 
 
 
Drug 
 
Company 
 
Pharmacology 
 
Comments 
    
Cyclosporin A. Novartis. Anti-rejection (immunosuppressive) drugs.  Cyclosporin A targets 
cyclophilin, FK506 (tacrolimus) targets FKBP-12 which then inhibit 
calcineurin and T cell function [249]. 
Cyclosporin A has been shown to inhibit the severity of liver disease 
progression (fibrosis) in transplanted PBC patients versus those given 
an alternative anti-rejection drug  FK506 [250].  This study will 
compare cyclosporin A and FK506 for their abilities to inhibit fibrosis 
in HCV patients after liver transplantation - NCT00260208. 
 
Farglitazar 
(GI262570). 
 
GSK. PPARγ agonist [251]. Hepatic stellate cells express the PPARγ, activators inhibit fibrogenicity 
[252,253].  See NCT00244751. 
 
INT747 (6-ethyl 
chenodeoxycholic 
acid). 
Intercept. FXR agonist [254]. Currently being tested in type II diabetics with presumed NAFLD for 
safety and tolerability, see NCT00501592.  Hepatic stellate cells express 
the FXR and activators inhibit fibrogenicity in vitro [255].  Therefore, 
potential anti-fibrogenic. 
 
Interferon γ 1b. Intermune. Interferon γ 1b agonist. NCT00043303 study completed.  Did not reverse fibrosis in HCV 
patients with advanced liver disease for 1 year [256]. 
 
Irbesartan. Sanofi-Synthelabo / French 
National Agency for 
Research on AIDS and 
Viral Hepatitis. 
 
AT1 receptor antagonist. Angiotensin II is secreted by activated hepatic stellate cells, which 
induces fibrogenic actions through the activation of NADPH oxidase. 
Trial - NCT00265642. 
 
Peginterferon α-2a. Hoffmann La-Roche. Interferon α agonist. Interferon-α may reduce portal pressure through a direct affect on the 
hepatic vasculature and may prevent complications of cirrhosis 
regardless of its effects on HCV RNA.  Study to determine whether 
drug will lower portal pressure in patients with hepatitis C virus 
infections and advanced fibrosis or cirrhosis – NTC00252642. 
 
Peginterferon α-2b. Schering Plough. Interferon α agonist. Potentially may inhibit fibrosis in HCV patients not responding to 
treatment with respect to viremia [257].  Potential effects ± ribavirin to 
be examined re, NCT00323804. 
 
Pentoxyfilline. Assistance Publique - 
Hôpitaux de Paris. 
Phosphodiesterase inhibition leading to increases in cAMP  - inhibition 
of cytokine expression such as TNFα [258]. 
 
Survival rate in cirrhotic patients - NCT00162552. 
Pirfenidone. Marnac, Inc., Cell Therapy 
and Technology, and 
Intermune. 
 
FGF/TGFβ1/TNFα antagonist [259]. Fibrosis was reduced in 30% of patients by the end of 12 months of 
treatment [260]. 
Warfarin. Imperial College, London. Anti-coagulant (vitamin K antagonist). Possession of the factor V Leiden polymorphism associated with 
increased fibrosis in HCV, suggests a role for coagulation [261].  An 
anti-thrombin drug inhibits fibrosis in an animal model [262].  Trial - 
NCT00180674. 
 
Trials data are freely available at http://clinicaltrials.gov/ct , a service provided by the US National Institute for Health. 
 
 
